VG Life Sciences, trading under OTCMKTS: VGLS, is a biotechnology company focused on the development and commercialization of point-of-care diagnostic platforms. Headquartered in Jacksonville, Florida, VG Life Sciences leverages proprietary immunoassay and biosensor technologies to deliver rapid, sensitive testing solutions for human health, environmental monitoring and biodefense applications. Since its founding in the early 2000s, the company has emphasized modular, portable systems capable of producing laboratory-quality results outside traditional laboratory settings.
The company’s flagship product line, the QwikSense® platform, integrates novel antibody-based assays with electrochemical detection to quantify biomarkers such as cardiac troponin I and B-type natriuretic peptide (BNP) for heart failure, as well as multiplexed panels for oncology and infectious disease markers. In addition to clinical uses, VG Life Sciences offers test kits for environmental applications, including rapid detection of waterborne pathogens (E. coli, Legionella) and toxins (aflatoxin, botulinum). These assays are designed for field deployment by military units, public health agencies and commercial testing laboratories.
VG Life Sciences partners with research institutions, government agencies and private distributors to expand its global presence. The company has secured collaborative agreements in North America, Asia and the Middle East to address urgent needs in remote and resource-limited settings. Through contract research and licensing arrangements, VG Life Sciences continues to evolve its platform chemistry, aiming to accelerate assay development timelines and broaden the spectrum of detectable analytes.
Under the leadership of President and CEO William “Bill” Cordes, who brings over three decades of experience in diagnostics and product development, and Chief Scientific Officer Dr. John S. McDevitt, a noted biomolecular engineer and professor emeritus at Stony Brook University, VG Life Sciences maintains a management team with deep expertise in regulatory affairs, manufacturing scale-up and commercial strategy. This leadership structure positions the company to capitalize on growing demand for decentralized diagnostic testing across multiple end markets.
AI Generated. May Contain Errors.
